Source: Viemed Healthcare Inc.
  • Viemed Healthcare (VMD) has announced a share repurchase program on Nasdaq
  • Viemed may repurchase up to 1,984,014 common shares
  • Daily purchases will be limited to 25 per cent of the average daily trading volume on Nasdaq
  • Shares purchased by the company will be cancelled and returned to treasury
  • Viemed provides in-home medical equipment and post-acute respiratory healthcare services in the United States
  • Viemed Healthcare Inc. (VMD) opened trading at C$4.58 per share

Viemed Healthcare (VMD) has announced a share repurchase program on Nasdaq.

Under the share repurchase program, Viemed may repurchase up to 1,984,014 common shares ‎representing approximately 5 per cent of the total issued and outstanding common shares as of March ‎4‎, 2022.‎

Daily purchases will be limited to 25 per cent of the average daily trading volume on Nasdaq for the four calendar weeks preceding the date of purchase.

“Based on the strength of our balance sheet and excess free cash flow, we believe we are well positioned to execute on this attractive opportunity to increase shareholder value while maintaining resources to fund our operations and continued growth,” said Casey Hoyt, Viemed CEO.

“This program demonstrates our confidence in the Viemed business and our commitment to creating long term sustainable value for our shareholders.”

All shares will be purchased through the facilities of Nasdaq. The company may discontinue its purchases at any time.‎ Shares purchased by the company will be cancelled and returned to treasury.

Viemed provides in-home medical equipment and post-acute respiratory healthcare services in the United States.

Viemed Healthcare Inc. (VMD) opened trading at C$4.58 per share.

More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.